Secondary Analyses of the Childhood Adenotonsillectomy Trial

医学 阻塞性睡眠呼吸暂停 扁桃体切除术 随机对照试验 小心等待 腺样体切除术 多导睡眠图 儿科 概化理论 临床试验 物理疗法 心理学 精神科 发展心理学 呼吸暂停 内科学 外科 癌症 前列腺癌
作者
Julianna Decuzzi,Susan Redline,Amal Isaiah
出处
期刊:JAMA otolaryngology-- head & neck surgery [American Medical Association]
卷期号:148 (8): 779-779 被引量:4
标识
DOI:10.1001/jamaoto.2022.1330
摘要

Adenotonsillectomy, performed for approximately 500 000 children annually in the US alone, is the first line of treatment of pediatric obstructive sleep apnea (OSA). The Childhood Adenotonsillectomy Trial (CHAT), the first randomized clinical trial to test the efficacy of adenotonsillectomy, compared the management of pediatric nonsevere OSA by early adenotonsillectomy (eAT) vs watchful waiting with supportive care. Since the publication of the primary article in 2013, the CHAT study data set were made available via the National Sleep Research Resource, which allowed researchers to address a range of additional clinical questions relevant to the care of children with OSA. This review focuses on secondary analyses associated with the CHAT data set as grouped by the outcome of interest.The results of most secondary analyses suggest that children who underwent eAT experienced the greatest improvements in symptom burden, sleepiness, parent-reported behavior, and quality of life. Changes in other domains, such as cognition, cardiovascular physiology, and metabolic indicators, were modest and selective. The associations between most treatment outcomes and polysomnographic parameters were weak. Symptoms were poor predictors of OSA severity. The results from these secondary analyses benefitted from the rigor of multicenter design and centralized polysomnography interpretation in CHAT. However, the exclusion of younger preschool-aged children and children with primary snoring limited the generalizability of findings. In addition, because caregivers were not masked, some of the parent-reported outcomes may have been inflated.The results of this narrative review suggest that CHAT provides a model for future OSA-related studies in children for design, conduct, and subsequent reuse of the study data set, and its findings have advanced our understanding of the pathophysiology and management of pediatric nonsevere OSA. Directions for future research include whether the findings from this landmark study are generalizable to younger children and children with primary snoring and severe OSA. Similar studies may help address practice variability associated with pediatric OSA and help identify children who are most likely to benefit from undergoing eAT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
霖29完成签到,获得积分10
1秒前
Magic完成签到 ,获得积分10
3秒前
四斤瓜完成签到 ,获得积分0
4秒前
传奇3应助奋斗的善若采纳,获得10
4秒前
科研通AI6.1应助九月采纳,获得10
5秒前
6秒前
娄十三完成签到 ,获得积分10
6秒前
123123完成签到,获得积分20
8秒前
852应助123采纳,获得10
11秒前
YifanWang应助一个小胖子采纳,获得10
12秒前
魔术师完成签到 ,获得积分10
12秒前
14秒前
美好师完成签到,获得积分10
15秒前
15秒前
Ryan完成签到,获得积分0
18秒前
SimpleKwee发布了新的文献求助10
19秒前
19秒前
糖醋鱼应助Wyoou采纳,获得10
23秒前
feiyang完成签到 ,获得积分10
27秒前
28秒前
隐形白开水完成签到,获得积分0
33秒前
星河完成签到 ,获得积分10
34秒前
Gavin啥也不会完成签到,获得积分10
39秒前
科研通AI6.1应助科研通管家采纳,获得100
42秒前
arniu2008应助科研通管家采纳,获得20
42秒前
一个小胖子完成签到,获得积分10
45秒前
往徕完成签到,获得积分10
45秒前
xiaxia完成签到 ,获得积分10
46秒前
科研通AI2S应助Wyoou采纳,获得10
52秒前
ee发布了新的文献求助10
52秒前
ee发布了新的文献求助10
53秒前
23完成签到 ,获得积分10
53秒前
幽默梦之完成签到 ,获得积分10
54秒前
harry2021完成签到,获得积分10
54秒前
123完成签到,获得积分10
57秒前
奋斗的善若完成签到,获得积分10
1分钟前
1分钟前
123发布了新的文献求助10
1分钟前
123123发布了新的文献求助10
1分钟前
文艺的白猫完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development Across Adulthood 800
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
天津市智库成果选编 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6444828
求助须知:如何正确求助?哪些是违规求助? 8258624
关于积分的说明 17591662
捐赠科研通 5504521
什么是DOI,文献DOI怎么找? 2901561
邀请新用户注册赠送积分活动 1878538
关于科研通互助平台的介绍 1718137